DBV Technologies S.A. (DBVT) Form 8-K — Oct 28, 2026
DBV Technologies reported Q3 2026 results with a net loss of $64.5 million (vs $33.2 million a year ago) and cash of $165.7 million, funding operations only into Q3 2027. The company disclosed substantial doubt about its ability to continue as a going concern within twelve months, saying it will need additional capital and is evaluating financing alternatives including more ATM sales. On the positive side, DBV submitted its BLA to the FDA for the VIASKIN Peanut Patch in children aged 4-7 with a requested Priority Review, backed by the 654-patient Phase 3 VITESSE trial, with an FDA acceptance/priority-review decision expected in Q4 2026.
Key figures
- Revenue
- 1600000
- Cash Position
- 165700000
- Cash runway
- into third quarter of 2027
- Bla filing fees
- 4700000
- Atm program size
- 150000000
- Net loss q3 2025
- 33200000
- Rd expenses q3 2025
- 28600000
- Rd expenses q3 2026
- 47000000
- Vitesse trial enrollment
- 654
- Gross proceeds ra capital
- 50000000
- Net loss nine months 2025
- 102100000
- Net loss nine months 2026
- 162500000
- Operating expenses q3 2026
- 66300000
- Precommercial inventory spend q3
- 4500000
- Net cash used operating investing nine months 2026
- 159400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.